Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

3.710 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
Via Benzinga
Peering Into bluebird bio's Recent Short Interest
Via Benzinga
Is Bluebird Bio Stock a Buy Now?
Are you feeling brave? 
Via The Motley Fool
Bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
NEW YORK, NY - (NewMediaWire) - March 27, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
The Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
BLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
From The Rosen Law Firm, P.A.
Via Business Wire
Forecasting The Future: 6 Analyst Projections For bluebird bio
Via Benzinga
(BLUE) - Analyzing bluebird bio's Short Interest
Via Benzinga
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
From bluebird bio, Inc.
Via Business Wire
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
Why Bluebird Bio Stock Flew Higher Than the Market Today
The company was thrown a financial lifeline. 
Via The Motley Fool
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
From bluebird bio, Inc.
Via Business Wire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation. 
Via The Motley Fool
MarketBeat Week in Review – 2/26 - 3/1
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
bluebird bio Stock Signals Potential to be a Multi-bagger
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do 
Via MarketBeat
Topics Economy
Exposures Economy
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
Exposures Product Safety
bluebird bio stock is ripe for a 400% institutional short squeeze
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in 
Via MarketBeat
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.